NCT00536692已完成2 期
Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)
CoMentis6 个研究点 分布在 1 个国家开始时间: 2007年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 6
研究概览
简要总结
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •macular edema due to diabetic retinopathy
排除标准
- •vision loss from other ocular disease
- •intraocular surgery within 3 months
- •intraocular anti-VEGF or steroids within 3 months
- •HbA1c >12
研究者
研究点 (6)
Loading locations...
相似试验
终止
1 期
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVOWet Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein OcclusionNCT03790852Kodiak Sciences Inc121
已完成
2 期
RMP-A03 Ocular Suspension in Patients With PterygiumPterygiumNCT05794204Suzhou Raymon Pharmaceuticals Company, Ltd.77
已完成
2 期
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)Neovascular Age Related Macular DegenerationNCT01678963Ohr Pharmaceutical Inc.142
进行中（未招募）
2 期
Volrustomig Priming Regimens Exploratory Phase II Platform StudyNon-small Cell Lung CancerNCT06448754AstraZeneca194
已完成
1 期
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)Wet Age-related Macular DegenerationNCT04747197EyePoint Pharmaceuticals, Inc.17